Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Call For India Compulsory Licenses For Last Resort TB Drugs

Executive Summary

Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses. 

Advertisement

Related Content

UN's TB Plan Emphasizes Drug Development Collaboration, Universal Access To Treatment
Mylan Gears To Make Otsuka’s MDR TB Drug In India
Otsuka Ties Up With Mylan To Advance MDR-TB Drug In India?
Indian Teen’s Fight For Lifesaving TB Drug Highlights Access Issues
India Plans New TB Strategy Amid Sharp Rise In Cases
Janssen India Boss On Sirturo's Pricing Stand And Real World Evidence
Delamanid Access Widened But TB Groups Want More

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100655

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel